An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer-Reference-Cited by-同舟云学术

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer

Published:2016-06-17 Issue:4 Volume:12 Page:380-387
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Wang Luhua¹,Wu Yi-Long²,Lu Shun³,Deng Lei¹,Ahn Myung-Ju⁴,Hsu Feng-Ming⁵,Iscoe Neill⁶⁷,Hossain Anwar⁸,Puri Tarun⁹,Zhang Pinghai¹⁰,Orlando Mauro¹¹

Affiliation:

1. Department of Radiotherapy; Cancer Hospital; Chinese Academy of Medical Sciences; Peking Union Medical College; Beijing China

2. Guangdong Lung Cancer Institute; Guangdong General Hospital and Guangdong Academy of Medical Sciences; Guangzhou China

3. Lung Cancer Center; Shanghai Chest Hospital; Shanghai Jiao Tong University; Shanghai China

4. Samsung Medical Center; Gangnam-Gu Seoul The Republic of Korea

5. Division of Radiation Oncology; Department of Oncology; National Taiwan University Hospital; Taipei City Taiwan

6. Global Medical Affairs; Eli Lilly Canada Inc; Toronto Canada

7. Eli Lilly and Company; Indianapolis Indiana USA

8. Statistical Sciences; Eli Lilly and Company; Indianapolis Indiana USA

9. Emerging Markets; Eli Lilly and Company; Gurgaon Haryana India

10. Oncology; Lilly China Drug Development and Medical Affairs Center; Eli Lilly and Company; Shanghai China

11. Emerging Markets; Eli Lilly and Company; Buenos Aires Argentina

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12513/fullpdf

Reference25 articles.

1. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

2. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey;Morgensztern;J Thorac Oncol,2010

3. A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI);Hida;Cancer Chemother Pharmacol,2012

4. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410;Curran;J Natl Cancer Inst,2011

5. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Vansteenkiste;Ann Oncol,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07

2. Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029);Anti-Cancer Drugs;2024-05-03

3. Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis;eClinicalMedicine;2023-10

4. Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy;Thoracic Cancer;2021-12-19

5. Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction;Translational Oncology;2021-04